Specifically, they found that among those with wild-type tumors, the OS of patients with LS tumors was numerically superior to those with RS disease (median OS: 31.5 vs. 16.7 months, respectively), while in patients with KRAS-mutated tumors, OS was comparable (median OS of 21.1 months for those with RS tumors and 23.7 for those with LS tumors). The gene discussed is KRAS; the disease is Leigh syndrome.